
Loading, please wait...

Loading, please wait...

The rise of antimicrobial resistance among ESKAPE pathogens remains a critical challenge for global health. Researchers are now investigating bacterial protein kinases as master regulators of essential cellular processes and virulence. These enzymes control metabolism, cell division, and the secretion of virulence factors during infections. Because these proteins are highly conserved across species, they offer stable targets for drug development.
Bacterial signaling systems share a common evolutionary origin with those in eukarya and archaea. Specifically, these kinases promote host-pathogen interactions by manipulating the defense systems of the host. This manipulation allows for the establishment of persistent infections even in hostile environments. Moreover, these proteins maintain fundamental bacterial functions, which means they are less likely to undergo rapid mutations.
Traditional antibiotics often fail because bacteria develop mutations quickly. However, bacterial protein kinases show a lower frequency of mutation since they are essential for survival. Furthermore, these kinases regulate efflux pumps that bacteria use to discard antibiotic molecules. By inhibiting these master regulators, clinicians can potentially restore the efficacy of existing treatments. Consequently, targeting these pathways minimizes the risk of pathogens gaining new types of resistance. In addition, experimental validation of various kinase inhibitors has already demonstrated success in controlling severe infections.
These kinases regulate the expression of efflux pumps, which actively pump antibiotics out of the bacterial cell. By controlling these pumps, the kinases help the bacteria survive even in the presence of high drug concentrations.
Because kinases are master regulators of fundamental biological processes, they are essential for bacterial survival. This essentiality results in a lower probability of mutation, making them more reliable targets than non-essential bacterial proteins.
ESKAPE pathogens possess intrinsic and acquired resistance mechanisms that allow them to escape the effects of most available antibiotics. They are the leading cause of hospital-acquired infections, often leading to poor patient outcomes.
Disclaimer: This content is for informational and educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A review of bacterial protein kinases in ESKAPE pathogens as novel therapeutic targets to manage antibiotic resistance and virulence factors....
6 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday